Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Blood Monocyte Vesicles for Sudden Deafness
NCT06707389Phase 1Not yet recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Dec 2024
- Primary completion
- Jun 2026
- Modality
- Lipid-based Nanoparticles, Cell Therapies
01
Overview
Phase 1, randomised trial of autologous blood monocyte vesicles in sudden sensorineural hearing loss (SSNHL) (3 arms), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Audiometry at 4 weeks. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
autologous blood monocyte vesicles
03
Conditions
sudden sensorineural hearing loss (SSNHL)
Beyond the preview
Go deeper on NCT06707389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06707389.